Cite
HARVARD Citation
Toulmonde, M. et al. (n.d.). 31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts. European journal of cancer. pp. S725-S726. [Online].